# Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer

> **NCT01266460** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 54 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Recurrent Cervical Carcinoma

## Interventions

- **BIOLOGICAL:** Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01266460
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-23
- **Primary completion:** 2018-10-02
- **Final completion:** 2018-10-02
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2020-09-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266460, "Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01266460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*